Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting
multiple sclerosis treated with teriflunomide tablets 14 mg daily